CIK 0001124105
- Accelerated filer
- Smaller reporting company
GYRE THERAPEUTICS, INC.
Sign in to watch- Ticker
- GYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 562020050
- Phone
- +1 858-284-0115
- Business address
- 12730 HIGH BLUFF DRIVE, SUITE 250, SAN DIEGO, CA, 92130
- Former names
- CATALYST BIOSCIENCES, INC., TARGACEPT INC
- 4 Planned sale President sold 4,000 shares at an average $12.35 ($49,380)
- 4 Planned sale President sold 4,000 shares at an average $12.22 ($48,860)
- 4 Planned sale President sold 4,000 shares at an average $11.59 ($46,360)
- 4 Planned sale President sold 3,878 shares at an average $11.72 ($45,435)
- 4 Planned sale President sold 4,000 shares at an average $12.51 ($50,020)
- 4 Planned sale President sold 4,000 shares at an average $12.01 ($48,029)
- 4 Planned sale President sold 4,000 shares at an average $11.49 ($45,960)
- 4 Planned sale President sold 4,000 shares at an average $11.40 ($45,600)
- 4 Planned sale President sold 4,000 shares at an average $11.35 ($45,380)
- 4 Planned sale President sold 4,000 shares at an average $10.69 ($42,760)
- 4 Planned sale President sold 4,000 shares at an average $10.74 ($42,960)
- 4 Planned sale President sold 4,000 shares at an average $10.72 ($42,860)
- 4 Planned sale President sold 4,000 shares at an average $10.62 ($42,480)
- 4 Planned sale President sold 1,113 shares at an average $10.02 ($11,157)
- 4/A Planned sale President sold 833 shares at $11.85 ($9,871)
- 4 Planned sale President sold 2,216 shares at an average $10.08 ($22,336)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Planned sale President sold 4,000 shares at an average $11.89 ($47,543)
- 4 Planned sale President sold 4,000 shares at an average $12.40 ($49,600)
Page 4 of 37 · 739 filings